{"id":20877,"date":"2026-07-13T15:17:41","date_gmt":"2026-07-13T06:17:41","guid":{"rendered":"https:\/\/tomorrowaccess.com\/?page_id=20877"},"modified":"2026-10-27T14:21:23","modified_gmt":"2026-10-27T05:21:23","slug":"apnimed-2026","status":"publish","type":"page","link":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026","title":{"rendered":"The Primary Endpoint Was Met. What the FDA Questioned Was Its &ldquo;Meaning.&rdquo;"},"content":{"rendered":"<style>@import url('https:\/\/fonts.googleapis.com\/css2?family=Newsreader:ital,opsz,wght@0,6..72,400;0,6..72,500;0,6..72,600;1,6..72,400&display=swap');html,body {max-width: 100vw !important;overflow-x: hidden !important;}main,main > .entry-content,main > .wp-block-post-content,main > .wp-block-post-content.is-layout-constrained,main > .wp-block-post-content.is-layout-constrained > *,main .wp-block-group,main .wp-block-post-content {max-width: 100% !important;padding-left: 0 !important;padding-right: 0 !important;margin-left: 0 !important;margin-right: 0 !important;}main#wp--skip-link--target {padding: 0 !important;margin-top: 0 !important;max-width: 100% !important;}.s1-figure-inline {display: block;width: 100%;max-width: 100%;margin: 60px 0;padding: 0;box-sizing: border-box;}.s1-figure-inline picture {display: block;width: 100%;}.s1-figure-inline img {display: block;width: 100%;max-width: 100%;height: auto;margin: 0;}@media (max-width: 720px) {.s1-hero-grid {grid-template-columns: 1fr !important;}.s1-hero-grid > div {border-right: none !important;border-bottom: 1px solid #e6e6e6 !important;padding: 24px 12px !important;}.s1-hero-grid > div:last-child {border-bottom: none !important;}.s1-hero-grid > div > div:first-child {font-size: 32px !important;white-space: normal !important;}.s1-body-table,.s1-body-table tbody,.s1-body-table tr,.s1-body-table td,.s1-body-table th {display: block !important;width: 100% !important;max-width: 100% !important;box-sizing: border-box !important;}.s1-body-table thead {display: none !important;}.s1-body-table tr {margin-bottom: 16px !important;padding: 8px 0 !important;border-top: 1px solid #1a1a1a !important;}.s1-body-table tr:last-child {border-bottom: 1px solid #1a1a1a !important;}.s1-body-table td {text-align: left !important;padding: 6px 8px !important;}.s1-light-shadow {flex-direction: column !important;}.s1-light-shadow > div {border-left: 1px solid #1a1a1a !important;border-top: 0 !important;}.s1-light-shadow > div:first-child {border-top: 1px solid #1a1a1a !important;}h1 {font-size: clamp(26px, 7vw, 34px) !important;}h2 {font-size: clamp(22px, 5.5vw, 28px) !important;}.s1-article-cta-headline {font-size: 24px !important; line-height: 1.4 !important;}}@media (max-width: 480px) {.s1-article-cta-headline {font-size: 20px !important;}}main .wp-block-post-content>.alignfull{margin-left:calc(-1*var(--wp--style--root--padding-left,20px)) !important;margin-right:calc(-1*var(--wp--style--root--padding-right,20px)) !important;max-width:none !important;width:auto !important;}<\/style>\n<div class=\"alignfull\" style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; color: #1a1a1a; overflow-wrap: break-word; text-wrap: pretty; font-size: 16px; -webkit-font-smoothing: antialiased; background: #fafafa; width: 100%;\">\n<div style=\"max-width: 1000px; margin: 0 auto; padding: 80px 20px 0; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;\">\n  <a href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/\" style=\"text-decoration: none; color: inherit; display: block;\"><\/p>\n<div style=\"text-align: left; margin-bottom: 40px;\">\n<div style=\"width: 100%; height: 5px; background: #1a1a1a;\"><\/div>\n<div style=\"margin-top: 26px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 32px; font-weight: 600; color: #1a1a1a; letter-spacing: 0.01em; line-height: 1; margin-bottom: 14px;\">S-1 <span style=\"color: #daa241;\">Journal<\/span><\/div>\n<div style=\"display: flex; align-items: center; flex-wrap: wrap; gap: 14px; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; margin-bottom: 26px;\">\n        <span style=\"font-size: 11px; letter-spacing: 0.18em; color: #1a1a1a; font-weight: 700; text-transform: uppercase;\">The 10 Questions<\/span><br \/>\n        <span style=\"font-size: 11px; color: #ccc;\">|<\/span><br \/>\n        <span style=\"font-size: 12px; letter-spacing: 0.02em; color: #666; font-weight: 400;\">Every S-1, decoded through the same 10 questions.<\/span>\n      <\/div>\n<div style=\"width: 100%; height: 1px; background: #daa241;\"><\/div>\n<\/p><\/div>\n<p>  <\/a>\n<\/div>\n<div style=\"max-width: 720px; margin: 0 auto; padding: 0 20px; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; color: #1a1a1a; overflow-wrap: break-word; text-wrap: pretty;\">\n<div style=\"margin: 0 0 32px 0;\">\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 30px; font-weight: 600; letter-spacing: 0; color: #daa241; margin: 0; line-height: 1.2;\">Apnimed<\/p>\n<\/div>\n<h1 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(32px, 6vw, 46px); font-weight: 600; line-height: 1.2; letter-spacing: -0.01em; color: #000; margin: 0 0 40px 0; text-wrap: pretty;\">The Primary Endpoint Was Met.<br \/>What the FDA Questioned Was Its &ldquo;Meaning.&rdquo;<\/h1>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13px; letter-spacing: 0.03em; color: #888; margin: 0 0 60px 0; border-bottom: 1px solid #e6e6e6; padding-bottom: 16px;\">Source: <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1745648\/000119312526300909\/apni-20260710.htm\" target=\"_blank\" rel=\"noopener\" style=\"color: #daa241; text-decoration: underline; text-underline-offset: 3px; text-decoration-thickness: 1px;\">Apnimed, Inc. S-1 (filed 2026-07-10) \u2197<\/a><\/div>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">On July 10, 2026, Apnimed filed its <span style=\"white-space:nowrap;\">S-1<\/span> with the SEC. Its banner is a single idea: <strong style=\"font-weight: 700; color: #000;\">to treat obstructive sleep apnea (OSA) with a pill<\/strong>. Its only clinical candidate, AD109 (development code; proposed brand name Oxnimbi), is described as an oral drug that acts on the neuromuscular activity behind the airway collapse that occurs when <span style=\"white-space:nowrap;\">upper-airway<\/span> muscles relax during sleep. The company submitted a New Drug Application (NDA) to the FDA in April 2026.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The trials met their primary endpoint. But the <span style=\"white-space:nowrap;\">S-1<\/span> contains a sentence in tension with that success: a disclosure that, at a <span style=\"white-space:nowrap;\">pre-NDA<\/span> meeting, the FDA questioned whether the results are &ldquo;<strong style=\"font-weight: 700; color: #000;\">clinically meaningful<\/strong>.&rdquo; Not whether it worked &mdash; but whether the way it worked matters.<\/p>\n<\/div>\n<div style=\"max-width: 720px; margin: 80px auto; padding: 0 20px;\">\n<div class=\"s1-hero-grid\" style=\"border-top: 1px solid #1a1a1a; border-bottom: 1px solid #1a1a1a; padding: 50px 0; display: grid; grid-template-columns: repeat(3, 1fr); gap: 0; text-align: center; align-items: start;\">\n<div style=\"padding: 0 12px; border-right: 1px solid #e6e6e6;\">\n<div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(28px, 4.5vw, 36px); font-weight: 500; line-height: 1.05; color: #000; letter-spacing: -0.02em; white-space: nowrap;\">10.5M<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 10.5px; letter-spacing: 0.2em; color: #daa241; margin-top: 18px; font-weight: 700; text-transform: uppercase;\">DIAGNOSED, UNTREATED<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.04em; color: #888; margin-top: 6px; font-weight: 400; line-height: 1.4;\">U.S., diagnosed but untreated<\/div>\n<\/p><\/div>\n<div style=\"padding: 0 12px; border-right: 1px solid #e6e6e6;\">\n<div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(28px, 4.5vw, 36px); font-weight: 500; line-height: 1.05; color: #000; letter-spacing: -0.02em; white-space: nowrap;\">-44.1%<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 10.5px; letter-spacing: 0.2em; color: #daa241; margin-top: 18px; font-weight: 700; text-transform: uppercase;\">AHI REDUCTION \u2014 ITT<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.04em; color: #888; margin-top: 6px; font-weight: 400; line-height: 1.4;\">trial primary analysis<\/div>\n<\/p><\/div>\n<div style=\"padding: 0 12px;\">\n<div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(28px, 4.5vw, 36px); font-weight: 500; line-height: 1.05; color: #000; letter-spacing: -0.02em; white-space: nowrap;\">$46.9M<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 10.5px; letter-spacing: 0.2em; color: #daa241; margin-top: 18px; font-weight: 700; text-transform: uppercase;\">CASH AT MAR 31, 2026<\/div>\n<div style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.04em; color: #888; margin-top: 6px; font-weight: 400; line-height: 1.4;\">going-concern doubt<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<div style=\"max-width: 720px; margin: 0 auto; padding: 0 20px; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; color: #1a1a1a; overflow-wrap: break-word; text-wrap: pretty;\">\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 60px 0 1.5em 0;\">The numbers have a strong side. In the United States alone, <strong style=\"font-weight: 700; color: #000;\">about 80 million people<\/strong> have OSA, of whom roughly 10.5 million are diagnosed but untreated. In the primary analysis, AD109 reduced the <span style=\"white-space:nowrap;\">apnea-hypopnea<\/span> index (AHI) by <span style=\"white-space:nowrap;\">44.1%<\/span> in SynAIRgy (versus <span style=\"white-space:nowrap;\">17.6%<\/span> on placebo). At the same time, cash stood at only <strong style=\"font-weight: 700; color: #000;\">about <span style=\"white-space:nowrap;\">$46.9<\/span> million<\/strong> at March 31, 2026, and the auditors flag substantial doubt about the company&rsquo;s ability to continue as a <strong style=\"font-weight: 700; color: #000;\">going concern<\/strong>.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">Just before the IPO, Apnimed exited its joint venture and sold its <span style=\"white-space:nowrap;\">50%<\/span> stake to Japan&rsquo;s Shionogi, securing about <span style=\"white-space:nowrap;\">$100<\/span> million of upfront cash. It is the picture of a <span style=\"white-space:nowrap;\">clinical-stage<\/span>, <span style=\"white-space:nowrap;\">pre-revenue<\/span> company running toward an FDA decision on which its fate rests.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.4em 0;\">Ten questions. We lay out only what the S-1 says.<\/p>\n<div class=\"s1-toc-top\" style=\"margin: 60px 0; padding: 30px; background: #fafafa; border-top: 1px solid #e6e6e6; border-bottom: 1px solid #e6e6e6; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;\"><div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 13px; color: #daa241; letter-spacing: 0.22em; margin-bottom: 16px;\">CONTENTS<\/div><ul style=\"list-style: none; padding: 0; margin: 0 0 20px; font-size: 14px;\"><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #000000;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q1<\/span><span>What is this company, really?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #000000;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q2<\/span><span>What is it competing on?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q3<\/span><span>How big is the market?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q4<\/span><span>Who uses it?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q5<\/span><span>How does it make money?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q6<\/span><span>Are the numbers healthy?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q7<\/span><span>Who runs it?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q8<\/span><span>Who controls it?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q9<\/span><span>What does it fear?<\/span><\/li><li style=\"padding: 9px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q10<\/span><span>What happens to the money raised?<\/span><\/li><li style=\"padding: 9px 0;  display: flex; align-items: baseline; gap: 16px; color: #666666;\"><span style=\"color: #daa241; font-weight: 700; min-width: 60px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">\u2014<\/span><span>Closing: beyond the ten questions<\/span><\/li><\/ul><p style=\"margin: 0; font-size: 13px; color: #666666; line-height: 1.7;\">Q1 and Q2 are free. Q3 onward is a one-time $25 unlock. <a href=\"https:\/\/buy.stripe.com\/5kQ6oGanm8gLbl1crh67S0h?client_reference_id=apnimed-en\" style=\"color: #daa241; font-weight: 700; text-decoration: none; white-space: nowrap;\">Unlock the full piece for $25 &rarr;<\/a><\/p><\/div><p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13px; letter-spacing: 0.22em; font-weight: 700; color: #daa241; margin: 100px 0 12px 0; text-transform: uppercase;\">Question 1<\/p>\n<h2 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(26px, 5vw, 32px); font-weight: 600; line-height: 1.25; letter-spacing: -0.005em; color: #000; margin: 0 0 28px 0;\">What is this company, really?<\/h2>\n<div style=\"margin: 0 0 30px 0; padding: 0 0 16px 0; border-bottom: 1px solid #1a1a1a;\">\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.2em; color: #daa241; font-weight: 700; margin: 0 0 8px 0; text-transform: uppercase;\">Primary source \u00b7 from the S-1<\/p>\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 1.6; color: #1a1a1a; margin: 0;\">Prospectus Summary (Our Business), Business (Overview) \u2014 from the S-1<\/p>\n<\/div>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">In one line: a company taking on sleep apnea with a pill.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">Obstructive sleep apnea (OSA) is a condition in which the <span style=\"white-space:nowrap;\">upper-airway<\/span> muscles relax during sleep and the airway repeatedly collapses. The standard of care is <strong style=\"font-weight: 700; color: #000;\">CPAP<\/strong> (a bedside machine that delivers pressurized air through a mask to hold the airway open). It is effective, but many people stop using it because the mask is uncomfortable.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">What Apnimed is developing is not that machine, but a tablet. It is an oral drug, taken at bedtime, that the <span style=\"white-space:nowrap;\">S-1<\/span> says acts on <strong style=\"font-weight: 700; color: #000;\">the nerves and muscles<\/strong> that are one cause of the airway collapse.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">AD109 (Oxnimbi) is <strong style=\"font-weight: 700; color: #000;\">a <span style=\"white-space:nowrap;\">fixed-dose<\/span> combination of two components<\/strong> &mdash; a novel <span style=\"white-space:nowrap;\">anti-muscarinic<\/span> and a selective norepinephrine reuptake inhibitor. It is not a single new molecule, but a combination of two agents with known effects, designed to raise the activity of the <span style=\"white-space:nowrap;\">upper-airway<\/span> muscles.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">At the front of the <span style=\"white-space:nowrap;\">S-1<\/span>, the company states its mission.<\/p>\n<blockquote style=\"position: relative; margin: 36px 0; padding: 20px 22px 16px 22px; background: #f5f1e6; box-sizing: border-box; max-width: 100%; overflow: hidden;\"><p>\n<span aria-hidden=\"true\" style=\"position: absolute; top: 2px; left: 10px; font-family: Georgia, 'Times New Roman', serif; font-size: 42px; font-weight: 400; color: #daa241; line-height: 1;\">&ldquo;<\/span><\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 17px; font-weight: 400; line-height: 1.65; letter-spacing: 0.02em; color: #1a1a1a; margin: 0 0 10px 0; padding-left: 24px; overflow-wrap: break-word; overflow-wrap: break-word;\">We aim to improve the daily lives of people suffering from these disorders by offering a convenient treatment option which, if approved, we expect to become <strong style=\"font-weight: 700; color: #000;\">the standard of care<\/strong> for the treatment of OSA.<\/p>\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 9.5px; font-weight: 700; letter-spacing: 0.16em; color: #daa241; margin: 0; padding-left: 24px; overflow-wrap: anywhere;\">APNIMED S-1 (JULY 2026) \u2014 PROSPECTUS SUMMARY<\/p>\n<\/blockquote>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The science has academic roots. <span style=\"white-space:nowrap;\">Co-founder<\/span> and chief scientific officer Luigi Taranto Montemurro, M.D., conducted the foundational research at Brigham and Women&rsquo;s Hospital (Harvard Medical School) that provided the proof of concept for the combination.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">One thing should be made clear. AD109 (Oxnimbi) is an <strong style=\"font-weight: 700; color: #000;\">investigational candidate<\/strong> that has not been approved by any regulator in the United States, Japan, or elsewhere. This article does not recommend its efficacy or safety; every figure here is drawn from the company&rsquo;s trial results and the <span style=\"white-space:nowrap;\">S-1<\/span>.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">In an era of &ldquo;widen the airway with a device,&rdquo; a company betting on &ldquo;work the muscles with a pill.&rdquo;<\/p>\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13px; letter-spacing: 0.22em; font-weight: 700; color: #daa241; margin: 100px 0 12px 0; text-transform: uppercase;\">Question 2<\/p>\n<h2 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: clamp(26px, 5vw, 32px); font-weight: 600; line-height: 1.25; letter-spacing: -0.005em; color: #000; margin: 0 0 28px 0;\">What does it compete on?<\/h2>\n<div style=\"margin: 0 0 30px 0; padding: 0 0 16px 0; border-bottom: 1px solid #1a1a1a;\">\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.2em; color: #daa241; font-weight: 700; margin: 0 0 8px 0; text-transform: uppercase;\">Primary source \u00b7 from the S-1<\/p>\n<p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 1.6; color: #1a1a1a; margin: 0;\">Business (Competitive Strengths) \u2014 from the S-1<\/p>\n<\/div>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The strengths the company claims fall into three groups.<\/p>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">The <span style=\"white-space:nowrap;\">S-1<\/span> lines up its strengths as market, mechanism, and convenience. Take them in turn.<\/p>\n<h3 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 22px; font-weight: 700; line-height: 1.5; color: #000; margin: 30px 0 16px 0; border-left: 4px solid #daa241; padding: 0 0 0 16px;\">A large, underserved market<\/h3>\n<p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #1a1a1a; margin: 0 0 1.5em 0;\">In the United States alone, <strong style=\"font-weight: 700; color: #000;\">about 80 million people<\/strong> have OSA. Some diagnosed patients refuse the standard of care, PAP, outright, and most of those who start it <span style=\"white-space:nowrap;\">under-use<\/span> or abandon it over time, the <span style=\"white-space:nowrap;\">S-1<\/span> notes, citing <span style=\"white-space:nowrap;\">third-party<\/span> research. The argument is that the treatment slot is open.<\/p>\n<div class=\"s1-paywall-fade\" aria-hidden=\"true\" style=\"position:relative; height:0; overflow:visible;\"><div style=\"position:absolute; left:0; right:0; bottom:0; height:220px; background:linear-gradient(to bottom, rgba(250,250,250,0) 0%, rgba(250,250,250,0.55) 45%, rgba(250,250,250,0.9) 80%, #fafafa 100%); pointer-events:none;\"><\/div><\/div><div class=\"s1-paywall-cta\" style=\"margin: 60px 0; padding: 60px 30px; background: #fafafa; border-top: 2px solid #daa241; border-bottom: 1px solid #e6e6e6; text-align: center; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;\">\n\n  <div style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 13px; color: #daa241; letter-spacing: 0.22em; margin-bottom: 16px;\">CONTINUE READING<\/div>\n\n  <h3 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 28px; font-weight: 400; line-height: 1.5; color: #000; margin: 0 0 32px; letter-spacing: 0.02em;\">\n    Keep reading\n  <\/h3>\n\n  <ul style=\"list-style: none; padding: 0; margin: 0 auto 32px; max-width: 380px; text-align: left; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px;\">\n      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q3<\/span>\n        <span>How big is the market?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q4<\/span>\n        <span>Who actually uses it?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q5<\/span>\n        <span>How does it make money?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q6<\/span>\n        <span>Are the numbers healthy?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q7<\/span>\n        <span>Who runs it?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q8<\/span>\n        <span>Who controls it?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q9<\/span>\n        <span>What is it afraid of?<\/span>\n      <\/li>      <li style=\"padding: 10px 0; border-bottom: 1px solid #e6e6e6; display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Q10<\/span>\n        <span>What becomes of the money it raises?<\/span>\n      <\/li>      <li style=\"padding: 10px 0;  display: flex; align-items: baseline; gap: 16px;\">\n        <span style=\"color: #daa241; font-weight: 700; min-width: 54px; font-family: 'Newsreader', Georgia, 'Times New Roman', serif;\">Closing<\/span>\n        <span>Beyond the ten questions<\/span>\n      <\/li>\n  <\/ul>\n<div class=\"s1-owarini-teaser\" style=\"max-width: 720px; margin: 0 auto 30px; padding: 30px 0 0; border-top: 1px solid #e6e6e6; text-align: left; position: relative;\"><p style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 12px; letter-spacing: 0.25em; font-weight: 700; color: #daa241; margin: 0 0 12px; text-transform: uppercase;\">In closing<\/p><h4 style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 24px; font-weight: 400; line-height: 1.5; color: #000; margin: 0 0 30px; letter-spacing: 0.02em;\">Beyond the ten questions<\/h4><p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #000; margin: 0 0 24px;\">What Apnimed is selling is not just an &ldquo;oral sleep-apnea drug.&rdquo; It is a single tablet that could threaten both the CPAP device market and the GLP-1 injection market at once. About 10.5 million untreated Americans support that story.<\/p><p style=\"font-family: 'Newsreader', Georgia, 'Times New Roman', serif; font-size: 20px; line-height: 1.65; letter-spacing: 0; color: #000; margin: 0;\">But the bearer of that bet holds not a single approved product.<\/p><div aria-hidden=\"true\" style=\"position: absolute; left: 0; right: 0; bottom: 0; height: 60px; background: linear-gradient(to bottom, rgba(250,250,250,0) 0%, rgba(250,250,250,0.85) 100%); pointer-events: none;\"><\/div><\/div>\n  <a href=\"https:\/\/buy.stripe.com\/5kQ6oGanm8gLbl1crh67S0h?client_reference_id=apnimed-en\" style=\"display: inline-block; background: #daa241; color: #fff; padding: 18px 48px; font-size: 16px; font-weight: 700; text-decoration: none; letter-spacing: 0.08em; transition: background 0.2s;\" onmouseover=\"this.style.background='#b88a36'\" onmouseout=\"this.style.background='#daa241'\">\n    Full access for $25 &rarr;\n  <\/a>\n\n  <div style=\"margin: 60px 0 0; text-align: left;\">\n    <a href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\" style=\"font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 16px; font-weight: 700; color: #daa241; text-decoration: none; letter-spacing: 0.02em;\">&larr; Back to S-1 Journal<\/a>\n  <\/div>\n\n<\/div><div class=\"s1-paywall-locked\" aria-hidden=\"true\" style=\"display:none;\"><\/div><div class=\"s1-article-footer\" style=\"margin: 16px 0 0; padding: 8px 30px 36px; background: transparent; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13px; color: #666; line-height: 1.8; text-align: center;\">\n  <div style=\"max-width: 680px; margin: 0 auto;\">\n    <p style=\"margin: 0 0 18px;\">This article is an explainer for informational purposes only. It is not investment advice or a solicitation to invest. Any investment decision is your own responsibility. The facts here are based on each company&rsquo;s S-1 filing but are not guaranteed to be accurate or complete. Please consult the primary filing on <a href=\"https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&type=S-1&dateb=&owner=include&count=40\" target=\"_blank\" rel=\"noopener\" style=\"color: #daa241; text-decoration: underline; text-underline-offset: 2px;\">SEC EDGAR<\/a>.<\/p>\n    <p style=\"margin: 0;\"><a href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal#sales-info\" style=\"color: #daa241; text-decoration: underline; text-underline-offset: 3px; font-weight: 700;\">Pricing &amp; terms &rarr;<\/a><\/p>\n  <\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>S-1 Journal The 10 Questions | Every S-1, decoded through the same 10 questions. Apnimed The Primary Endpoint  [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":24369,"parent":20744,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_yoast_wpseo_focuskw":"Apnimed S-1","_yoast_wpseo_title":"Apnimed (Oxnimbi) S-1: Endpoint Met, FDA Questioned It %%sep%% %%sitename%%","_yoast_wpseo_metadesc":"About 10.5 million Americans have diagnosed but untreated obstructive sleep apnea. Apnimed's investigational oral drug AD109 (Oxnimbi) met its primary endpoint, but the FDA questioned the clinical meaningfulness of the results. Just before the IPO, Apnimed sold its Shionogi joint-venture stake for $100 million upfront. With about $46.9 million of cash at March 31, the S-1 flags substantial doubt about going concern. Decoded from the S-1.","_yoast_wpseo_canonical":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_yoast_wpseo_twitter-title":"","_yoast_wpseo_twitter-description":"","_uag_custom_page_level_css":"","eventcal-data-date-start":"","eventcal-data-date-end":"","eventcal-data-url":"","eventcal-data-place":"","eventcal-data-capacity":"","eventcal-data-ticket":"","eventcal-data-report":"","eventcal-data-note":"","mentoring-company":"","mentoring-position":"","mentoring-name":"","mentoring-url":"","mentoring-text-top":"","mentoring-text-01":"","mentoring-text-02":"","mentoring-text-03":"","mentoring-images":"","mentoring-logo":"","expert-pitch-data-thumbnail":"https:\/\/www.youtube.com\/embed\/M7DlaXKYhLw","expert-pitch-data-youtube":"","expert-pitch-data-date":"2022.03.01 TUE 12:00-13:00","expert-pitch-data-name":"Global Brain, Partner US office \u4e00\u5bae \u7fd4\u5e73\u6c0f","expert-pitch-data-excerpt":"\u91d1\u878d\u5e02\u5834\u304c\u5927\u304d\u304f\u5909\u308f\u308d\u3046\u3068\u3057\u3066\u3044\u307e\u3059\u3002 \u3053\u308c\u307e\u3067\u306f\u65e7\u6765\u306e\u9280\u884c\u304c\u307b\u307c\u5168\u3066\u306e\u6a5f\u80fd\u3092\u6301\u3063\u3066\u3044\u307e\u3057\u305f\u304c\u3001\u304a\u91d1\u3092\u8caf\u3081\u308b\u3001\u9001\u91d1\u3059\u308b\u3001\u6c7a\u6e08\u3059\u308b\u3001\u306a\u3069\u306e\u6a5f\u80fd\u304c\u7d30\u5206\u5316\u3057\u3066\u3001\u3055\u307e\u3056\u307e\u306a\u4eba\u304c\u500b\u3005\u306e\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3067\u304d\u308b\u6642\u4ee3\u306b\u306a\u308a\u307e\u3057\u305f\u3002 \u3055\u3089\u306bAI\u306e\u6280\u8853\u3084\u81a8\u5927\u306a\u91cf\u3092\u51e6\u7406\u3067\u304d\u308b\u6280\u8853\u3001\u30d6\u30ed\u30c3\u30af\u30c1\u30a7\u30fc\u30f3\u6280\u8853\u306a\u3069\u3082\u6210\u719f\u3057\u3066\u304d\u305f\u3053\u3068\u3082\u3042\u308a\u3001\u305d\u306e\u52d5\u304d\u306f\u52a0\u901f\u3057\u3066\u3044\u307e\u3059\u3002 \u52d5\u304d\u304c\u6fc0\u3057\u3044\u30d5\u30a3\u30f3\u30c6\u30c3\u30af\u306b\u3064\u3044\u3066\u3001\u6295\u8cc7\u304c\u6d3b\u767a\u3067\u3001\u4eca\u5e74\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u6295\u8cc7\u3068Fintech\u306a\u3069\u306b\u3082\u6ce8\u529b\u3055\u308c\u3066\u3044\u304fGlobal Brain Partner \u4e00\u5bae\u6c0f\u3068\u6700\u65b0\u60c5\u5831\u3092\u304a\u5c4a\u3051\u3057\u307e\u3059\u3002","expert-pitch-data-download-file":"","expert-pitch-data-peatix":"","expert-pitch-data-whitepaper-show":false,"common-label-text":"","_locale":"en_US","_original_post":"https:\/\/tomorrowaccess.com\/?page_id=20870","footnotes":""},"class_list":["post-20877","page","type-page","status-publish","has-post-thumbnail","hentry","en-US"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apnimed (Oxnimbi) S-1: Endpoint Met, FDA Questioned It | Tomorrow Access<\/title>\n<meta name=\"description\" content=\"About 10.5 million Americans have diagnosed but untreated obstructive sleep apnea. Apnimed&#039;s investigational oral drug AD109 (Oxnimbi) met its primary endpoint, but the FDA questioned the clinical meaningfulness of the results. Just before the IPO, Apnimed sold its Shionogi joint-venture stake for $100 million upfront. With about $46.9 million of cash at March 31, the S-1 flags substantial doubt about going concern. Decoded from the S-1.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apnimed (Oxnimbi) S-1: Endpoint Met, FDA Questioned It | Tomorrow Access\" \/>\n<meta property=\"og:description\" content=\"About 10.5 million Americans have diagnosed but untreated obstructive sleep apnea. Apnimed&#039;s investigational oral drug AD109 (Oxnimbi) met its primary endpoint, but the FDA questioned the clinical meaningfulness of the results. Just before the IPO, Apnimed sold its Shionogi joint-venture stake for $100 million upfront. With about $46.9 million of cash at March 31, the S-1 flags substantial doubt about going concern. Decoded from the S-1.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026\" \/>\n<meta property=\"og:site_name\" content=\"Tomorrow Access\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TomorrowAccess\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T05:21:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/apnimed-en-og-dark.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1260\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/apnimed-en-og-dark.png\" \/>\n<meta name=\"twitter:site\" content=\"@TomorrowAccess\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/apnimed-2026\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/apnimed-2026\",\"name\":\"Apnimed (Oxnimbi) S-1: Endpoint Met, FDA Questioned It | Tomorrow Access\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/apnimed-2026#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/apnimed-2026#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/s1-card-apnimed-2026-en.jpg\",\"datePublished\":\"2026-07-13T06:17:41+00:00\",\"dateModified\":\"2026-10-27T05:21:23+00:00\",\"description\":\"About 10.5 million Americans have diagnosed but untreated obstructive sleep apnea. Apnimed's investigational oral drug AD109 (Oxnimbi) met its primary endpoint, but the FDA questioned the clinical meaningfulness of the results. Just before the IPO, Apnimed sold its Shionogi joint-venture stake for $100 million upfront. With about $46.9 million of cash at March 31, the S-1 flags substantial doubt about going concern. Decoded from the S-1.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/apnimed-2026#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/apnimed-2026\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/apnimed-2026#primaryimage\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/s1-card-apnimed-2026-en.jpg\",\"contentUrl\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/s1-card-apnimed-2026-en.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"S-1\u30b8\u30e3\u30fc\u30ca\u30eb Apnimed\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\\\/apnimed-2026#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u30db\u30fc\u30e0\",\"item\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"S-1 Journal \u2014 Every S-1, Explained Through the Same 10 Questions\",\"item\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/s-1-journal\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The Primary Endpoint Was Met. What the FDA Questioned Was Its &ldquo;Meaning.&rdquo;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#website\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/\",\"name\":\"Tomorrow Access\",\"description\":\"Tomorrow Access Homepage\",\"publisher\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tomorrowaccess.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#organization\",\"name\":\"Tomorrow Access\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ta-ogp.jpg\",\"contentUrl\":\"https:\\\/\\\/tomorrowaccess.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ta-ogp.jpg\",\"width\":2400,\"height\":1260,\"caption\":\"Tomorrow Access\"},\"image\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TomorrowAccess\",\"https:\\\/\\\/x.com\\\/TomorrowAccess\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/tomorrow-access\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCz2iUaHKT-gK0ijM0_iFDeA\"],\"legalName\":\"Tomorrow Access LLC\",\"alternateName\":[\"\u30c8\u30a5\u30e2\u30ed\u30fc\u30a2\u30af\u30bb\u30b9\",\"Tomorrow Access LLC\"],\"description\":\"Silicon Valley-based consulting firm supporting Japanese companies with U.S. expansion, new business development and corporate venture capital (CVC), and mentoring startups.\",\"foundingDate\":\"2021\",\"slogan\":\"BUILD YOUR OWN PATH\",\"address\":{\"@type\":\"PostalAddress\",\"addressRegion\":\"CA\",\"addressCountry\":\"US\"},\"areaServed\":[{\"@type\":\"Country\",\"name\":\"United States\"},{\"@type\":\"Country\",\"name\":\"Japan\"}],\"knowsLanguage\":[\"ja\",\"en\"],\"knowsAbout\":[\"Silicon Valley\",\"U.S. market entry for Japanese companies\",\"Corporate venture capital (CVC)\",\"New business development\",\"Startup investment\",\"Startup mentoring\"],\"founder\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#\\\/schema\\\/person\\\/ken-sobajima\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"contactType\":\"sales\",\"url\":\"https:\\\/\\\/tomorrowaccess.com\\\/en\\\/contact\",\"availableLanguage\":[\"ja\",\"en\"]}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#\\\/schema\\\/person\\\/ken-sobajima\",\"name\":\"Ken Sobajima\",\"alternateName\":\"\u508d\u5cf6 \u5065\u53cb\",\"jobTitle\":\"Founder & CEO\",\"worksFor\":{\"@id\":\"https:\\\/\\\/tomorrowaccess.com\\\/#organization\"},\"description\":\"Founder & CEO of Tomorrow Access. 25 years at a major Japanese telecom, including heading U.S. investments for its corporate venture fund; based in Silicon Valley since 2015.\",\"award\":[\"Global Corporate Venturing Rising Stars 2019\",\"Global Corporate Venturing Top 50 Emerging Leaders 2021\"],\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/sobazy\\\/\"],\"knowsLanguage\":[\"ja\",\"en\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apnimed (Oxnimbi) S-1: Endpoint Met, FDA Questioned It | Tomorrow Access","description":"About 10.5 million Americans have diagnosed but untreated obstructive sleep apnea. Apnimed's investigational oral drug AD109 (Oxnimbi) met its primary endpoint, but the FDA questioned the clinical meaningfulness of the results. Just before the IPO, Apnimed sold its Shionogi joint-venture stake for $100 million upfront. With about $46.9 million of cash at March 31, the S-1 flags substantial doubt about going concern. Decoded from the S-1.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026","og_locale":"en_US","og_type":"article","og_title":"Apnimed (Oxnimbi) S-1: Endpoint Met, FDA Questioned It | Tomorrow Access","og_description":"About 10.5 million Americans have diagnosed but untreated obstructive sleep apnea. Apnimed's investigational oral drug AD109 (Oxnimbi) met its primary endpoint, but the FDA questioned the clinical meaningfulness of the results. Just before the IPO, Apnimed sold its Shionogi joint-venture stake for $100 million upfront. With about $46.9 million of cash at March 31, the S-1 flags substantial doubt about going concern. Decoded from the S-1.","og_url":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026","og_site_name":"Tomorrow Access","article_publisher":"https:\/\/www.facebook.com\/TomorrowAccess","article_modified_time":"2026-10-27T05:21:23+00:00","og_image":[{"width":2400,"height":1260,"url":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/apnimed-en-og-dark.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_image":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/apnimed-en-og-dark.png","twitter_site":"@TomorrowAccess","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026","url":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026","name":"Apnimed (Oxnimbi) S-1: Endpoint Met, FDA Questioned It | Tomorrow Access","isPartOf":{"@id":"https:\/\/tomorrowaccess.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026#primaryimage"},"image":{"@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026#primaryimage"},"thumbnailUrl":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg","datePublished":"2026-07-13T06:17:41+00:00","dateModified":"2026-10-27T05:21:23+00:00","description":"About 10.5 million Americans have diagnosed but untreated obstructive sleep apnea. Apnimed's investigational oral drug AD109 (Oxnimbi) met its primary endpoint, but the FDA questioned the clinical meaningfulness of the results. Just before the IPO, Apnimed sold its Shionogi joint-venture stake for $100 million upfront. With about $46.9 million of cash at March 31, the S-1 flags substantial doubt about going concern. Decoded from the S-1.","breadcrumb":{"@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026#primaryimage","url":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg","contentUrl":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg","width":1536,"height":1024,"caption":"S-1\u30b8\u30e3\u30fc\u30ca\u30eb Apnimed"},{"@type":"BreadcrumbList","@id":"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u30db\u30fc\u30e0","item":"https:\/\/tomorrowaccess.com\/en\/"},{"@type":"ListItem","position":2,"name":"S-1 Journal \u2014 Every S-1, Explained Through the Same 10 Questions","item":"https:\/\/tomorrowaccess.com\/en\/s-1-journal"},{"@type":"ListItem","position":3,"name":"The Primary Endpoint Was Met. What the FDA Questioned Was Its &ldquo;Meaning.&rdquo;"}]},{"@type":"WebSite","@id":"https:\/\/tomorrowaccess.com\/#website","url":"https:\/\/tomorrowaccess.com\/","name":"Tomorrow Access","description":"Tomorrow Access Homepage","publisher":{"@id":"https:\/\/tomorrowaccess.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tomorrowaccess.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tomorrowaccess.com\/#organization","name":"Tomorrow Access","url":"https:\/\/tomorrowaccess.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tomorrowaccess.com\/#\/schema\/logo\/image\/","url":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2022\/10\/ta-ogp.jpg","contentUrl":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2022\/10\/ta-ogp.jpg","width":2400,"height":1260,"caption":"Tomorrow Access"},"image":{"@id":"https:\/\/tomorrowaccess.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TomorrowAccess","https:\/\/x.com\/TomorrowAccess","https:\/\/www.linkedin.com\/company\/tomorrow-access","https:\/\/www.youtube.com\/channel\/UCz2iUaHKT-gK0ijM0_iFDeA"],"legalName":"Tomorrow Access LLC","alternateName":["\u30c8\u30a5\u30e2\u30ed\u30fc\u30a2\u30af\u30bb\u30b9","Tomorrow Access LLC"],"description":"Silicon Valley-based consulting firm supporting Japanese companies with U.S. expansion, new business development and corporate venture capital (CVC), and mentoring startups.","foundingDate":"2021","slogan":"BUILD YOUR OWN PATH","address":{"@type":"PostalAddress","addressRegion":"CA","addressCountry":"US"},"areaServed":[{"@type":"Country","name":"United States"},{"@type":"Country","name":"Japan"}],"knowsLanguage":["ja","en"],"knowsAbout":["Silicon Valley","U.S. market entry for Japanese companies","Corporate venture capital (CVC)","New business development","Startup investment","Startup mentoring"],"founder":{"@id":"https:\/\/tomorrowaccess.com\/#\/schema\/person\/ken-sobajima"},"contactPoint":{"@type":"ContactPoint","contactType":"sales","url":"https:\/\/tomorrowaccess.com\/en\/contact","availableLanguage":["ja","en"]}},{"@type":"Person","@id":"https:\/\/tomorrowaccess.com\/#\/schema\/person\/ken-sobajima","name":"Ken Sobajima","alternateName":"\u508d\u5cf6 \u5065\u53cb","jobTitle":"Founder & CEO","worksFor":{"@id":"https:\/\/tomorrowaccess.com\/#organization"},"description":"Founder & CEO of Tomorrow Access. 25 years at a major Japanese telecom, including heading U.S. investments for its corporate venture fund; based in Silicon Valley since 2015.","award":["Global Corporate Venturing Rising Stars 2019","Global Corporate Venturing Top 50 Emerging Leaders 2021"],"sameAs":["https:\/\/www.linkedin.com\/in\/sobazy\/"],"knowsLanguage":["ja","en"]}]}},"uagb_featured_image_src":{"full":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg",1536,1024,false],"thumbnail":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg",150,100,false],"medium":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg",300,200,false],"medium_large":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg",768,512,false],"large":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg",1024,683,false],"1536x1536":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg",1536,1024,false],"2048x2048":["https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/10\/s1-card-apnimed-2026-en.jpg",1536,1024,false]},"uagb_author_info":{"display_name":"Ken","author_link":"https:\/\/tomorrowaccess.com\/news\/author\/ken"},"uagb_comment_info":0,"uagb_excerpt":"S-1 Journal The 10 Questions | Every S-1, decoded throu&hellip;","_links":{"self":[{"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages\/20877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/comments?post=20877"}],"version-history":[{"count":1,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages\/20877\/revisions"}],"predecessor-version":[{"id":23696,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages\/20877\/revisions\/23696"}],"up":[{"embeddable":true,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/pages\/20744"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/media\/24369"}],"wp:attachment":[{"href":"https:\/\/tomorrowaccess.com\/wp-json\/wp\/v2\/media?parent=20877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}